Abstract
Matrix metalloproteinases (MMPs) constitute a group of over 20 structurally-related proteins which include a Zn++ ion binding site that is essential for their proteolytic activities. These enzymes play important role in extracellular matrix turnover in order to maintain a proper balance in its synthesis and degradation. MMPs are associated to several physiological and pathophysiological processes, including diabetes mellitus (DM). The mechanisms of DM and its complications is subject of intense research and evidence suggests that MMPs are implicated with the development and progression of diabetic microvascular complications such as nephropathy, cardiomyopathy, retinopathy and peripheral neuropathy. Recent data has associated DM to changes in the tendon structure, including abnormalities in fiber structure and organization, increased tendon thickness, volume and disorganization obtained by image and a tendency of impairing biomechanical properties. Although not fully elucidated, it is believed that DM-induced MMP dysregulation may contribute to structural and biomechanical alterations and impaired process of tendon healing.
Access provided by Autonomous University of Puebla. Download chapter PDF
Similar content being viewed by others
Keywords
MMPs Structure, Function and Regulation
Matrix metalloproteinases (MMPs) constitute a group of over 20 structurally-related proteins which include a Zn++ ion binding site that is essential for their proteolytic activities. These enzymes play important role in extracellular matrix (ECM) turnover in order to maintain a proper balance in its synthesis and degradation [1]. Thus, MMPs substrates are mainly collagens, but also many other ECM proteins, including fibronectin, laminin, tenascin, aggrecan and osteonectin [2].
MMPs can be classified in four groups accordingly to their domain organization, sequence similarities and their substrate specificity. The group of (i) gelatinases comprises MMP-2 and MMP-9 and is characterized by an additional domain, called collagen binding domain, which represents the preferential binding domain for fibrillar collagen I [3]. MMP-2 is generally expressed in endothelial cells, fibroblasts, keratinocytes and chondrocytes; while MMP-9 is present in alveolar macrophages, trophoblasts, osteoclasts and polymorphonuclear leukocytes [4, 5]. The group of (ii) matrilysins is composed of MMP-7 and MMP-26 which are able to process collagen IV but not collagen I [6], and are involved in degradation of ECM constituents in the uterus at postpartum and implantation of embryos [7]. The (iii) typical MMPs group comprises three subgroups, namely stromelysins (MMP-3,-10 and-11), which participate of ECM turnover but are not able to cleave fibrillar collagen I; Collagenases (MMP-1,-8 and -13), which are responsible for degrading several native collagen (type I-V, XI) and other MMPs such as MMP-12, MMP-19, MMP-20 and MMP-27 [4, 8]. The last group is referred as (iv) furin-activated MMPs and consists of membrane type MMPs (MT-1,-2,-3,-4,-5-MMPs), transmembrane MMPs type II and secreted MMPs [4]. With a different structural arrangement from that of MMPs, the disintegrin and metalloproteinase domain with thrombospondin-1 motifs (ADAMTS) is another family of metalloproteinases and consists of 19 members which specifically process proteoglycans, in particular aggrecan, and pro-collagen [9, 10].
The MMPs are synthesized as inactive zymogens with a pro-peptide domain that must be withdrawn by several proteases, such as plasmin, thrombin, chimase, and MT-MMPs for protease activation. Activated MMPs can be either cell-secreted or membrane-bound exhibiting catalytic activity at the cell surface, intracellularly and extracellularly [5]. Due to its high proteolytic potential, MMPs are subjected to tight control and restrictive regulatory mechanisms that maintain homeostasis at the intracellular and extracellular level. One of the regulation mechanisms of the MMPs activity is by their endogenous inhibitors, tissue inhibitors of MMPs (TIMPs), which comprise a family of four members (TIMP-1 to 4) [8]. TIMPs are expressed in a tissue specific pattern and can operate through direct MMPs inhibition or by controlling their activation [11].
MMPs and TIMPs are associated to several physiological processes such as embryogenesis, wound healing, proliferation, cell motility, remodeling, angiogenesis and key reproductive events [4, 8]. On the other hand, recent evidence has shown that pathologically increased MMP activity or imbalance between MMP and TIMP expression can exacerbate a variety of diseases [12]. Indeed, MMPs are correlated to the pathogenesis of abnormalities of the growth plate and wound healing, heart failure, arthritic synovial joints, cancer, periodontal disease, ischemic brain injury [13] and even tendinopathies [14]. This chapter aims to relate MMPs changes in the diabetes mellitus (DM) pathogenesis with special focus on the tendon tissue.
MMPs and Pathogenesis of Diabetic Complications
DM is a group of metabolic disorders considered one of the major health problems worldwide [15, 16]. Chronic hyperglycemia resulting from defects in the secretion and/or insulin action is the main feature of the disease and may lead to vascular damage in vessels, nerves and many internal organs including the eyes, kidneys and heart.
Currently, the development mechanism of DM and its complications is subject of intense research. It has been observed the involvement of the MMPs in the development and progression of various complications of DM [17] and proteases are speculated to have importance for diabetes pathogenesis [18]. Previous studies have demonstrated higher concentrations of MMPs in the serum from type 1 DM [19], type 2 DM patients [20] and in a cell culture model for type 2 DM [21]. By using cultures of endothelial cells, Death and colleagues [22] demonstrated that hyperglycemia enhanced activity and expression of MMP-1,-2, and macrophage-derived MMP-9; while MMP-3 and TIMP-1 had expression and protein levels decreased and unaffected, respectively. These results indicate augmented ECM degradation in hyperglycemic conditions and suggest that MMPs can be useful markers for risk and/or progression of diabetic complications such as diabetic nephropathy and microangiopathy [23].
High levels of blood glucose are also associated to dysfunction of several intracellular signal transduction cascades including generation of reactive oxygen species (ROS), modulation of protein kinases and accumulation of advanced glycation end products (AGEs) (see Chap. 18) [24]. The receptor for AGE (RAGE) represents the main binding site for AGEs on resident and/or inflammatory cells and this interaction is capable to stimulate the production, expression and activity of MMPs in specific cell lines [25]. RAGEs are mainly located on the surface of macrophages, where they bind to the ECM proteins.
It is recognized that AGEs are able to affect the production and structure of ECM proteins, mainly due to formation of collagen cross-links. Aside from altered mechanical properties of collagen, AGEs can modify the interaction of collagen with other molecules such as proteoglycans (PGs), MMPs and cell integrins [26]. This collagen modification by AGEs have been correlated to inhibited wound repair and exacerbated inflammation in a rotator cuff tendon-bone [27] and medial collateral ligament [28] healing models. If the mechanical effects of AGEs in the collagenous tissue is not well understood, it is known that AGE cross-links are involved in reduced remodeling capacity due to reduced sensitivity to collagenases [29, 30], possibly via alterations in collagen solubility and augmented collagen resistance to protease breakdown [26, 31].
In some tissues, matrix-glycation products and AGEs formation can attract and stimulate cells to release cytokines (e.g., IL-1 and IL-6), MMPs and growth factors (e.g., TNF-α) during wound repair, which in turn accelerates the inflammatory response [32]. It should be noted that certain growth factors (e.g., TGF-β and CTGF) seem to have a role in the pathogenesis of long-term diabetic complications since they have increased concentrations and are associated to ECM accumulation in diabetic nephropathy [17] and tenocyte death and scar formation in tendons [33]. In addition, elevated levels of inducible nitric oxide synthase (iNOS) and prostaglandin E2 (PGE2), disturbance of the insulin secretion/action and its key signalling proteins, genetic polymorphism of MMPs and participation of oxidative stress have all been attributed to play a role in the elevated MMP expression during hyperglycemia in diabetic patients and models [25, 34].
MMPs and Diabetic Tendon Disorders: Current Findings
A growing body of evidence has associated DM to changes in the tendon structure, including abnormalities in fiber structure and organization [35], increased tendon thickness, volume and disorganization obtained by image findings [36, 37], and a tendency of impairing biomechanical properties [38, 39]. Interestingly, these tendon alterations may represent features of the ECM, which is in a constant state of dynamic equilibrium between synthesis and degradation [40].
Besides the relevance of MMPs in the ECM turnover and their role in the tendon pathophysiology [41], data linking these proteases to the development and progression of diabetic tendon disorders is still scarce. In a recent review, Shi and colleagues [39] highlighted the participation of the MMPs in the tendon alterations based in two studies. The first work, from Ahmed and co-workers [42], aimed to investigate the mechanical properties and expressional changes of genes involved in the tendon healing process in a diabetic rodent model . The authors found strong expression of MMP-13 and MMP-3 in tenocytes both in diabetic and healthy tendons; whereas MMP-13 expression was upregulated and MMP-3 expression decreased in the tendon healing model . Moreover, Tsai and others [43] found upregulation of MMP-9 and MMP-13 and increased enzymatic activity of MMP-9 in a tendon cells culture treated with high glucose concentration. Overall, these results indicate that hyperglycemia might induce collagen degradation by increasing MMPs activity and lead to a low-quality tendon structure [39].
MMPs are also implicated in the development of diabetic fibrosis, a pathological finding characterized by ECM accumulation with or without changes in the ECM composition. Cardiac fibrosis, for example, is a major feature of diabetic cardiomyopathy and results in cardiac dysfunction [44]. Fibrosis is often a result of an imbalance between MMPs and TIMPs activity after tissue insults such as hyperglycemia, dyslipidemia and hypertension [17], but increased production of collagen and other ECM components may be also involved. To date, it is not clear if DM results in fibrosis in uninjuried or healing tendons. Previously, a streptozotocin (STZ)-induced diabetes study in Achilles tendons of rats demonstrated areas of higher density of collagen I and collagen fibers disorganization when compared to the controls [45]. It was suggested that increased vascularization associated with cell proliferation and possible migration caused hypercellularity and accounted for over-deposition of collagen in the diabetic group [45]. In fact, recruitment of inflammatory cells have been connected to dysregulation of tenocyte homeostasis followed by secretion of ECM proteins, which results in an increased turnover and remodeling of the tendon ECM [41, 46]. Moreover, MMPs are able to increase release of TGF-β1 (resident in the tendon’s matrix) which in turn may lead to an increased fibroblasts proliferation and collagen I deposition [47]. In this manner, a relationship between MMP/TIMP system and pro-fibrotic growth factors might contribute to fibrosis development due to ECM turnover dysregulation [17].
As previously mentioned, DM is known to produce a poor wound healing due to complications in the connective tissue metabolism, and higher expression of gelatinases in diabetes might be due to the prolonged inflammatory period [48]. In a recent work with STZ-induced diabetes in rats, Mohsenifar et al [49] showed impaired mechanical properties and altered inflammatory response in the diabetic group after Achilles tenotomy. The authors also found lower collagen content in the diabetic group at 15 days after surgery. Taken together, these results corroborate with other studies [42, 50] that point out for a delayed healing process in tendons of diabetic animals. It is noteworthy to mention that different MMPs operate in tendons, participating not only of the ECM degradation but also promoting micro-trauma healing and maintaining normal tendon function [41]. In this manner, besides augmented collagen turnover, other mechanism associated to the pathogenesis of tendinopathies may involve a “failed healing response” via decreased MMP-3 activity, for example [41]. Thus, although not fully elucidated, it is reasonable to highlight the participation of regulators of the ECM turnover (such as MMPs and others) in the tendon’s delayed healing response.
Conclusion
MMPs play a role in the mechanisms of several diabetic complications. Although little studied, evidence suggests that diabetes-induced MMP dysregulation may contribute to structural and biomechanical alterations and impair the healing process in tendons.
Abbreviations
- AGE:
-
advanced glycation end products
- ADAMTS:
-
Disintegrin and Metalloproteinase domain with Thrombospondin-1 motifs
- CTGF:
-
connective tissue growth factor
- DM:
-
diabetes mellitus
- ECM:
-
extracellular matrix
- IL:
-
interleukin cytokine family
- iNOS:
-
inducible nitric oxide synthase
- MMP(s):
-
matrix metalloproteinase(s)
- PGE2:
-
prostaglandin-E2
- RAGE(s):
-
receptor(s) for advanced glycation end products
- ROS:
-
reactive oxygen species
- TGF-β1:
-
transforming growth factor beta 1
- TIMP(s):
-
tissue inhibitor(s) of metalloproteinase
- TNF-α:
-
tumor necrosis factor alpha
- STZ:
-
Streptozotocin.
References
Klein T, Bischoff R (2011) Physiology and pathophysiology of matrix metalloproteases. Amino Acids 41(2):271–290
Stamenkovic I (2003) Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448–464
Gioia M, Monaco S, Fasciglione GF et al (2007) Characterization of the mechanisms by which gelatinase A, neutrophil collagenase, and membrane-type metalloproteinase MMP-14 recognize collagen I and enzymatically process the two alpha-chains. J Mol Biol 368(4):1101–1113
Piperi C, Papavassiliou AG (2012) Molecular mechanisms regulating matrix metalloproteinases. Curr Top Med Chem 12(10):1095–1112
Fanjul-Fernandez M, Folgueras AR, Cabrera S et al (2010) Matrix metalloproteinases: evolution, gene regulation and functional analysis in mouse models. Biochim Biophys Acta 1803(1):3–19
Wilson CL, Matrisian LM (1996) Matrilysin: an epithelial matrix metalloproteinase with potentially novel functions. Int J Biochem Cell Biol 28(2):123–136
Qiu W, Bai SX, Zhao MR et al (2005) Spatiotemporal expression of matrix metalloproteinase- 26 in human placental trophoblasts and fetal red cells during normal placentation. Biol Reprod 72(4):954–959
Amălinei C, Căruntu ID, Bălan RA (2007) Biology of metalloproteinases. Rom J Morphol Embryol 48(4):323–334
Tortorella M, Pratta M, Liu RQ et al (2000) The thrombospondin motif of aggrecanase-1 (ADAMTS-4) is critical for aggrecan substrate recognition and cleavage. J Biol Chem 275(33):25791–25797
Colige A, Ruggiero F, Vandenberghe I et al (2005) Domains and maturation processes that regulate the activity of ADAMTS-2, a metalloproteinase cleaving the aminopropeptide of fibrillar procollagens types I-III and V. J Biol Chem 280(41):34397–34408
Brew K, Nagase H (2010) The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim Biophys Acta 1803(1):55–71
Tsioufis C, Bafakis I, Kasiakogias A et al (2012) The role of matrix metalloproteinases in diabetes mellitus. Curr Top Med Chem 12(10):1159–1165
Malemud CJ (2006) Matrix metalloproteinases (MMPs) in health and disease: an overview. Front Biosci 11:1696–1701
Del Buono A, Oliva F, Osti L et al (2013) Metalloproteases and tendinopathy. Muscles Ligaments Tendons J 3(1):51–57
Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053
Meetoo D, McGovern P, Safadi R (2007) An epidemiological overview of diabetes across the world. Br J Nurs 16(16):1002–1007
Ban CR, Twigg SM (2008) Fibrosis in diabetes complications: pathogenic mechanisms and circulating and urinary markers. Vasc Health Risk Manag 4(3):575–596
The Diabetes Control and Complications Trial Research Group (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986
Gharagozlian S, Svennevig K, Bangstad HJ et al (2009) Matrix metalloproteinases in subjects with type 1 diabetes. BMC Clin Pathol 9:7
Tayebjee MH, Lip GY, MacFadyen RJ (2005) What role do extracellular matrix changes contribute to the cardiovascular disease burden of diabetes mellitus? Diabet Med 22(12):1628–1635
Uemura S, Matsushita H, Li W et al (2001) Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88(12):1291–1298
Death AK, Fisher EJ, McGrath KC et al (2003) High glucose alters matrix metalloproteinase expression in two key vascular cells: potential impact on atherosclerosis in diabetes. Atherosclerosis 168(2):263–269
Derosa G, Avanzini MA, Geroldi D et al (2005) Matrix metalloproteinase 2 may be a marker of microangiopathy in children and adolescents with type 1 diabetes mellitus. Diabetes Res Clin Pract 70(2):119–125
King GL, Wakasaki H (1999) Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes. Diabetes Care 22:C31–C37
Ryan ME, Ramamurthy NS, Sorsa T et al (1999) MMP-mediated events in diabetes. Ann N Y Acad Sci 878:311–334
Snedeker JG, Gautieri A (2014) The role of collagen crosslinks in ageing and diabetes – the good, the bad, and the ugly. Muscles Ligaments Tendons J 4(3):303–308
Bedi A, Fox AJ, Harris PE et al (2010) Diabetes mellitus impairs tendon-bone healing after rotator cuff repair. J Shoulder Elbow Surg 19(7):978–988
Frank C, McDonald D, Wilson J (1995) Rabbit medial collateral ligament scar weakness is associated with decreased collagen pyridinoline crosslink density. J Orthop Res 13(2):157–165
Reddy GK, Stehno-Bittel L, Enwemeka CS (2002) Glycation-induced matrix stability in the rabbit Achilles tendon. Arch Biochem Biophys 399(2):174–180
Reddy GK (2004) Cross-linking in collagen by nonenzymatic glycation increases the matrix stiffness in rabbit Achilles tendon. Exp Diabesity Res 5(2):143–153
Monnier VM, Mustata GT, Biemel KL et al (2005) Cross-linking of the extracellular matrix by the maillard reaction in aging and diabetes: an update on “a puzzle nearing resolution”. Ann N Y Acad Sci 1043:533–544
Nesto RW, Rutter MK (2002) Impact of the atherosclerotic process in patients with diabetes. Acta Diabetol 2:S22–28
Sharir A, Zelzer E (2011) Tendon homeostasis: the right pull. Curr Biol 21:025
Kadoglou NP, Daskalopoulou SS, Perrea D et al (2005) Matrix metalloproteinases and diabetic vascular complications. Angiology 56(2):173–189
Grant WP, Sullivan R, Sonenshine DE et al (1997) Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg 36(4):272–278
Papanas N, Courcoutsakis N, Papatheodorou K et al (2009) Achilles tendon volume in type 2 diabetic patients with or without peripheral neuropathy: MRI study. Exp Clin Endocrinol Diabetes 117(10):645–648
Abate M, Schiavone C, Pelotti P et al (2010) Limited joint mobility in diabetes and ageing: recent advances in pathogenesis and therapy. Int J Immunopathol Pharmacol 23(4):997–1003
de Oliveira RR, Lemos A, de Castro Silveira PV (2011) Alterations of tendons in patients with diabetes mellitus: a systematic review. Diabet Med 28(8):886–895
Shi L, Rui YF, Li G et al (2015) Alterations of tendons in diabetes mellitus: what are the current findings? Int Orthop 39(8):1465–1473
Jones GC, Corps AN, Pennington CJ et al (2006) Expression profiling of metalloproteinases and tissue inhibitors of metalloproteinases in normal and degenerate human Achilles tendon. Arthritis Rheum 54(3):832–842
Sbardella D, Tundo GR, Fasciglione GF et al (2014) Role of metalloproteinases in tendon pathophysiology. Mini Rev Med Chem 14(12):978–987
Ahmed AS, Schizas N, Li J et al (2012) Type 2 diabetes impairs tendon repair after injury in a rat model. J Appl Physiol (1985) 113(11):1784–1791
Tsai WC, Liang FC, Cheng JW et al (2013) High glucose concentration up-regulates the expression of matrix metalloproteinase-9 and −13 in tendon cells. BMC Musculoskelet Disord 14:255
Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47(4):693–700
de Oliveira RR, Martins CS, Rocha YR et al (2013) Experimental diabetes induces structural, inflammatory and vascular changes of Achilles tendons. PLoS One 8(10), e74942
Riley GP, Harrall RL, Constant CR, Chard MD et al (1994) Tendon degeneration and chronic shoulder pain: changes in the collagen composition of the human rotator cuff tendons in rotator cuff tendinitis. Ann Rheum Dis 53(6):359–366
Mendias CL, Gumucio JP, Davis ME et al (2012) Transforming growth factor-beta induces skeletal muscle atrophy and fibrosis through the induction of atrogin-1 and scleraxis. Muscle Nerve 45(1):55–59
Arul V, Kartha R, Jayakumar R (2007) A therapeutic approach for diabetic wound healing using biotinylated GHK incorporated collagen matrices. Life Sci 80(4):275–284
Mohsenifar Z, Feridoni MJ, Bayat M et al (2014) Histological and biomechanical analysis of the effects of streptozotocin-induced type one diabetes mellitus on healing of tenotomised Achilles tendons in rats. Foot Ankle Surg 20(3):186–191
Egemen O, Ozkaya O, Ozturk MB et al (2012) The biomechanical and histological effects of diabetes on tendon healing: experimental study in rats. J Hand Microsurg 4(2):60–64
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Abreu, B.J., de Brito Vieira, W.H. (2016). Metalloproteinase Changes in Diabetes. In: Ackermann, P., Hart, D. (eds) Metabolic Influences on Risk for Tendon Disorders. Advances in Experimental Medicine and Biology, vol 920. Springer, Cham. https://doi.org/10.1007/978-3-319-33943-6_17
Download citation
DOI: https://doi.org/10.1007/978-3-319-33943-6_17
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-33941-2
Online ISBN: 978-3-319-33943-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)